Annals of Oncology 14:969-970, 2003
© 2003 European Society for Medical Oncology
Editorial |
Targeting antihormone resistance in breast cancer: a simple solution
| The first 10% of the full text of this article appears below. |
During the past 30 years a dramatic change has occurred in the approach to the treatment of breast cancer. Thirty years ago, non-specific combination cytotoxic chemotherapy was going to cure breast cancer, advanced breast cancer was the only stage being treated with drugs and the estrogen receptor (ER) was considered a potential predictive test for identifying the one in three women who would respond to endocrine ablative surgery.
These changes occurred as a result of two principal factors: ER evolved from being viewed as a predictive marker of endocrine responsiveness to becoming a molecular target for tumor
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
W. E. Hardman (n-3) Fatty Acids and Cancer Therapy J. Nutr., December 1, 2004; 134(12): 3427S - 3430S. [Abstract] [Full Text] [PDF] |
||||
